According to GlobalData’s medical device pipeline database, 52 Coronary Bioabsorbable Stents devices are in various stages of development globally. GlobalData’s report Bioabsorbable Stents (BAS) provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.
Smarter leaders trust GlobalData
Of these devices, 19 are in active development, while the remaining 36 are in an inactive stage of development. There are five products in the early stages of development, and the remaining 14 are in the late stages of development.
Coronary bioabsorbable stents are also known as bioresorbable or biodegradable coronary stents. They are made from the material found in dissolvable sutures known as polylactic acid. The advantage of this stent is that it does not leave any metal body behind and hence, the possibility of late-stent thrombosis and restenosis decreases. Bioabsorbable stents help in better drug delivery compared to metallic stents. One unit refers to one bioabsorbable stent system.
Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.
See Also:
Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Coronary Bioabsorbable Stents pipeline devices are all expected to be approved within the next ten years.
Currently, private organizations, public entities and institutions are working on the development of Coronary Bioabsorbable Stents devices. Overall, most of these Coronary Bioabsorbable Stents pipeline devices are being developed by private entities.
Key players involved in the active development of Coronary Bioabsorbable Stents include Amaranth Medical, MIV Therapeutics, Xenogenics, MicroPort Scientific, OrbusNeich, Shanghai Bio-heart Biological Technology, Biotronik, Biotronik SE, Biotyx Medical (Shenzhen) and Boston Scientific.
For a complete picture of the developmental pipeline for Coronary Bioabsorbable Stents devices, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.
